Сравнение
Liraglutide vs. Mazdutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
204656-20-2
2259884-03-0
Молекулярная масса
3751 g/mol
4790 g/mol
Период полувыведения
13 h
132 h
Последовательность
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGsynthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteМеханизм действия
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
4
из них на людях
4
4
Зафиксированные эффекты
3
4
Открытые противоречия
1
0
Задокументированные нежелательные явления
1
0
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Liraglutide and Mazdutide?
- Liraglutide is classified as "Метаболизм", while Mazdutide is classified as "Метаболизм". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Liraglutide or Mazdutide?
- The highest available evidence level is "РКИ на людях" for Liraglutide and "РКИ на людях" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Liraglutide and Mazdutide in Germany and the United States?
- Германия: Liraglutide — Рецептурный, Mazdutide — Только для исследований. США: Liraglutide — Рецептурный, Mazdutide — Только для исследований. These are factual summaries with source and review date on the individual pages.